Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000817315 | SCV000957868 | uncertain significance | Hyperkalemic periodic paralysis | 2025-01-13 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 1639 of the SCN4A protein (p.Arg1639His). This variant is present in population databases (rs368186423, gnomAD 0.03%). This missense change has been observed in individual(s) with clinical features of SCN4A-related conditions (PMID: 32798841, 35866763, 36116128). ClinVar contains an entry for this variant (Variation ID: 660181). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt SCN4A protein function with a negative predictive value of 95%. Experimental studies have shown that this missense change does not substantially affect SCN4A function (PMID: 36116128). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002487806 | SCV002780951 | uncertain significance | Hypokalemic periodic paralysis, type 1; Potassium-aggravated myotonia; Paramyotonia congenita of Von Eulenburg; Hypokalemic periodic paralysis, type 2; Hyperkalemic periodic paralysis; Congenital myasthenic syndrome 16 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003141840 | SCV003821318 | uncertain significance | not provided | 2022-09-27 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV004997377 | SCV005622313 | likely benign | not specified | 2024-01-02 | criteria provided, single submitter | clinical testing |